What is cabaletta bio?

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases.

Where is cabaletta Bio headquartered?

The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio, Inc.’s ISS Governance QualityScore as of November 1, 2023 is 10.

Can cabaletta bio achieve compelling clinical responses?

This morning, Cabaletta Bio announced positive clinical data on CABA-201 demonstrating the potential to achieve compelling clinical responses with all patients discontinuing all immunosuppressants in the first 8 patients dosed across the ongoing Phase 1/2 RESET-Myositis™, RESET-SLE™ and RESET-SSc™ clinical trials.